DE602004020266D1 - Therapeutische und diagnostische anti-hsp 70-antikörper - Google Patents

Therapeutische und diagnostische anti-hsp 70-antikörper

Info

Publication number
DE602004020266D1
DE602004020266D1 DE602004020266T DE602004020266T DE602004020266D1 DE 602004020266 D1 DE602004020266 D1 DE 602004020266D1 DE 602004020266 T DE602004020266 T DE 602004020266T DE 602004020266 T DE602004020266 T DE 602004020266T DE 602004020266 D1 DE602004020266 D1 DE 602004020266D1
Authority
DE
Germany
Prior art keywords
antibodies
hsp
therapeutic
cells
diagnostic anti
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004020266T
Other languages
English (en)
Inventor
Gabriele Multhoff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Multimmune GmbH
Original Assignee
Multimmune GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34639281&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602004020266(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Multimmune GmbH filed Critical Multimmune GmbH
Publication of DE602004020266D1 publication Critical patent/DE602004020266D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
DE602004020266T 2003-12-05 2004-12-06 Therapeutische und diagnostische anti-hsp 70-antikörper Active DE602004020266D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03028144 2003-12-05
PCT/EP2004/013854 WO2005054295A2 (en) 2003-12-05 2004-12-06 Therapeutic and diagnostic anti-hsp 70 antibodies

Publications (1)

Publication Number Publication Date
DE602004020266D1 true DE602004020266D1 (de) 2009-05-07

Family

ID=34639281

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004020266T Active DE602004020266D1 (de) 2003-12-05 2004-12-06 Therapeutische und diagnostische anti-hsp 70-antikörper

Country Status (8)

Country Link
US (3) US7700737B2 (de)
EP (2) EP1706423B8 (de)
JP (2) JP4898452B2 (de)
AT (1) ATE426617T1 (de)
CY (2) CY1109125T1 (de)
DE (1) DE602004020266D1 (de)
ES (2) ES2484340T3 (de)
WO (1) WO2005054295A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4898452B2 (ja) * 2003-12-05 2012-03-14 マルチミューン ジーエムビーエイチ 治療および診断用抗Ｈｓｐ７０抗体
US8765687B2 (en) 2005-10-17 2014-07-01 Sloan Kettering Institute For Cancer Research WT1 HLA class II-binding peptides and compositions and methods comprising same
PL2010209T3 (pl) 2006-04-10 2017-04-28 Sloan Kettering Inst For Cancer Res Immunogeniczne peptydy WT-1 i sposoby ich użycia
BR122019024895B8 (pt) 2008-06-26 2021-07-27 Orphazyme As uso de um agente bioativo capaz de aumentar a concentração intracelular de hsp70
EP2580232A1 (de) * 2010-06-08 2013-04-17 National University of Ireland, Galway Manipulation von hsp70- und ire1alpha-proteininteraktionen
EP3626255A1 (de) 2010-11-30 2020-03-25 Orphazyme A/S Procédés pour accroître l'activité cellulaire de hsp70
CN108676069A (zh) 2012-01-13 2018-10-19 纪念斯隆凯特林癌症中心 免疫原性wt-1肽及其使用方法
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
US9919037B2 (en) 2013-01-15 2018-03-20 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
ES2881860T3 (es) 2014-09-15 2021-11-30 Orphazyme As Formulación de arimoclomol
ES2842212T3 (es) 2015-01-26 2021-07-13 Cellectis Receptores de antígenos quiméricos monocatenarios específicos anti-CLL1 (scCAR) para inmunoterapia contra el cáncer
WO2016120325A1 (en) 2015-01-27 2016-08-04 Klinikum Rechts Der Isar Der Technischen Universität München Quantitative assay for heat shock protein 70 (hsp70) protein in body fluids
CN108430915B (zh) * 2016-02-02 2022-07-26 M技术株式会社 微粒分散液的精密改性方法
WO2017178029A1 (en) 2016-04-13 2017-10-19 Orphazyme Aps Heat shock proteins and cholesterol homeostasis
LT3448382T (lt) 2016-04-29 2021-04-12 Orphazyme A/S Arimoklomolis, skirtas su gliukocerebrozidaze susijusiems sutrikimams gydyti
US20200237860A1 (en) 2017-08-31 2020-07-30 Multimmune Gmbh Hsp70 based combination therapy
CA3172949A1 (en) * 2020-03-27 2021-09-30 Robert Z. Orlowski Monoclonal antibodies targeting hsp70 and therapeutic uses thereof
AU2021380947B2 (en) 2020-11-19 2023-12-14 Zevra Denmark A/S Processes for preparing arimoclomol citrate and intermediates thereof
WO2023056361A1 (en) * 2021-09-29 2023-04-06 Board Of Regents, The University Of Texas System Anti-hsp70 antibodies and therapeutic uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0623679B1 (de) 1987-05-21 2003-06-25 Micromet AG Multifunktionelle Proteine mit vorbestimmter Zielsetzung
JPH02503867A (ja) 1988-04-15 1990-11-15 プロテイン　デザイン　ラブズ　インコーポレーテッド Ｉｌ‐２レセプター特異的キメラ抗体
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
GB9009548D0 (en) * 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
GB9020282D0 (en) 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
EP0903408A3 (de) 1992-08-21 2005-11-02 Biogen, Inc. Tat-derivate Transport-Polypeptide
EP0672142B1 (de) 1992-12-04 2001-02-28 Medical Research Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US5910488A (en) 1993-06-07 1999-06-08 Vical Incorporated Plasmids suitable for gene therapy
EP0822830B1 (de) 1995-04-27 2008-04-02 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
JPH11509088A (ja) 1995-06-23 1999-08-17 プレジデント アンド フェローズ オブ ハーバード カレッジ 血管内皮増殖因子受容体をコードする遺伝子の転写調節
AU6873396A (en) 1995-10-16 1997-05-07 Unilever N.V. A bifunctional or bivalent antibody fragment analogue
CA2328528C (en) 1998-05-20 2009-07-21 Immunomedics, Inc. Therapeutics using a bispecific anti-hla class ii invariant chain x anti-pathogen antibody
WO2001080883A1 (en) 2000-04-26 2001-11-01 Elusys Therapeutics, Inc. Bispecific molecules and uses thereof
ATE430161T1 (de) * 2000-09-13 2009-05-15 Multimmune Gmbh Peptid aus hsp70 welches nk zellaktivtät stimuliert und seine verwendung
AU2003227610A1 (en) 2002-04-12 2003-10-27 Multimmune Gmbh Non-toxic amounts of protein-aggregating substances stimulate hsp70 expression and function as anti-tumor agents
EP1695093A1 (de) 2003-12-05 2006-08-30 multimmune GmbH Verbindungen und verfahren zur behandlung und diagnose von neoplastischen und infektiösen krankheiten
JP4898452B2 (ja) * 2003-12-05 2012-03-14 マルチミューン ジーエムビーエイチ 治療および診断用抗Ｈｓｐ７０抗体

Also Published As

Publication number Publication date
ES2484340T3 (es) 2014-08-11
CY1116052T1 (el) 2017-02-08
WO2005054295A8 (en) 2005-08-18
JP2008502314A (ja) 2008-01-31
EP1706423A2 (de) 2006-10-04
US20070231337A1 (en) 2007-10-04
EP2070947B1 (de) 2014-06-11
US7700737B2 (en) 2010-04-20
JP2012006933A (ja) 2012-01-12
JP4898452B2 (ja) 2012-03-14
US8440188B2 (en) 2013-05-14
EP2070947A1 (de) 2009-06-17
ES2324538T3 (es) 2009-08-10
EP1706423B8 (de) 2009-07-08
JP5414750B2 (ja) 2014-02-12
ATE426617T1 (de) 2009-04-15
CY1109125T1 (el) 2014-07-02
WO2005054295A3 (en) 2006-12-28
US20100143356A1 (en) 2010-06-10
US20120087931A1 (en) 2012-04-12
EP1706423B1 (de) 2009-03-25
WO2005054295A2 (en) 2005-06-16

Similar Documents

Publication Publication Date Title
CY1116052T1 (el) Θεραπευτικα και διαγνωστικα αντι-ηsρ70 αντισωματα
CY1111147T1 (el) Διαμεμβρανικο αντιγονο λεκτινης τυπου c εκφραζομενο σε καρκινο στον προστατη ανθρωπου και χρησεις αυτου
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
ATE380548T1 (de) Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie
TNSN05300A1 (en) Treatment with anti-vegf antibodies
CY2013004I1 (el) Προϊοντα συζευξης auristatin και χρηση αυτων για θεραπεια καρκινου, αυτοανοσης ασθενειας ή μολυσματωδους ασθενειας
ATE468137T1 (de) Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten
ATE291614T1 (de) Diagnose und behandlung von zellproliferativen erkrankungen mit beteiligung von klonalen makrophagen
ATE422358T1 (de) Kombinationstherapie mittels reovirus und anti- antireovirus antikörpern zur behandlung von ras- vermittelten, proliferativen erkrankungen
MXPA03001634A (es) Polipeptido tumoral cripto.
CY1106152T1 (el) Νεα ανοσογονα αντι-hiv (ανατοξινες), μεθοδοι παρασκευης και εφαρμογη στην προληψη και στην αγωγη του aids
ATE454159T1 (de) Von survivin abgeleitete peptide und deren verwendung
CY1115524T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα εναντι της ανθρωπινης il-4
ATE198050T1 (de) Therapeutische anwendungen von bpi-protein- produkten zur behandlung von humaner meningococcämia
CY1114422T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει αρσενικωδες για τη θεραπευτικη αντιμετωπιση κακοηθειας
CY1115407T1 (el) Θοριο-227 για χρηση στην ακτινοθεραπεια ασθενειων των μαλακων ιστων
WO2003039591A3 (de) Allogene vakzine enthaltend eine ein costimulatorisches polypeptid exprimierende tumorzelle
WO2003080800A3 (en) Prevention and treatment of disease using angiogenesis-and/or tumor antigens
ATE435284T1 (de) Zusammensetzungen und verfahren zur therapie und diagnose von lungenkrebs
AU2003245858A8 (en) Uses of ngal-binding substances in the diagnosis and treatment of cancer diseases
CY1108412T1 (el) Συνθεσεις εμβολιου που περιλαμβανουν omp85 πρωτεϊνες απο neisseria gonorrhoea και neisseria miningitidis
DE60135232D1 (de) Nukleinsäure und korrespondierendes protein 85p1b3, nützlich zur behandlung und detektion von krebserkrankungen
ATE373711T1 (de) Gewebe-spezifische protein 103p2d6, hochexprimiert in verschiedene krebsarten
AU2003229876A1 (en) Tumour associated antigens
DE69803052T2 (de) Therapeutischer viraler wirkstoff, welcher das fortschreiten von tumoren stoppt

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: MULTIMMUNE GMBH C/O STRAHLENTHERAPIE DER TU MU, DE

8327 Change in the person/name/address of the patent owner

Owner name: MULTIMMUNE GMBH, 80634 MUENCHEN, DE

8363 Opposition against the patent